Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

被引：0
|
作者：
X Baraliakos
J Brandt
J Listing
J Sieper
J Braun
机构：
[1] Rheumatology Medical Center Ruhrgebiet,
[2] German Rheumatism Research Center,undefined
[3] University Medicine Berlin,undefined
来源：
Arthritis Research & Therapy | / 7卷
关键词：
Infliximab; Ankylose Spondylitis; Open Label Extension; Infliximab Treatment; Relevant Side Effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Baseline tumor necrosis factor alpha levels predict the clinical response of infliximab therapy in patients with crohn's disease
    Nomura, Eiki
    Sato, Takeshi
    Kannno, Nana
    Sakuta, Kazuhiro
    Mizumoto, Naoko
    Shibuya, Rika
    Yagi, Makoto
    Iwano, Daisuke
    Sasaki, Yu
    Abe, Yasuhiko
    Nishise, Syoichi
    Ueno, Yoshiyuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 131 - 131
  • [42] Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
    Morton Scheinberg
    Gilberto Castañeda-Hernández
    Arthritis Research & Therapy, 16
  • [43] Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn's disease
    Thomas, CW
    Weinshenker, BG
    Sandborn, WJ
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (01) : 28 - 31
  • [44] Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study
    Suzanne Arends
    Elisabeth Brouwer
    Eveline van der Veer
    Henk Groen
    Martha K Leijsma
    Pieternella M Houtman
    Tim L Th A Jansen
    Cees GM Kallenberg
    Anneke Spoorenberg
    Arthritis Research & Therapy, 13
  • [45] Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid Deposit After Anti-Tumor Necrosis Factor α Therapy in a Patient With Ankylosing Spondylitis
    Lee, Yu Ho
    Kim, Eun Young
    Jeong, Da Wun
    Kim, Yang-Gyun
    Lee, Sang-Ho
    Song, Ran
    Yang, Hyung In
    Lim, Sung Jig
    Moon, Ju-Young
    Lee, Sang-Hoon
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (02) : 86 - 88
  • [46] Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action
    Haraoui, Boulos
    Krelenbaum, Marilyn
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2009, 39 (03) : 176 - 181
  • [47] Neutropenia in Patients Receiving Anti-Tumor Necrosis Factor Therapy
    Hastings, Richard
    Ding, Tina
    Butt, Sayqa
    Gadsby, Kate
    Zhang, Weiya
    Moots, Robert J.
    Deighton, Chris
    ARTHRITIS CARE & RESEARCH, 2010, 62 (06) : 764 - 769
  • [48] The value of contrast-enhanced ultrasonography to detect the sacroiliac joint for predicting relapse after discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis
    Ren, Jiayu
    Zhu, Jiaan
    Li, Diancheng
    Li, Wenxue
    Liu, Fang
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2019, 9 (06) : 1110 - 1117
  • [49] Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
    Stasi, R
    Amadori, S
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) : 334 - 337
  • [50] Anti-tumor Necrosis Factor Therapy Increased Spine and Femoral Neck Bone Mineral Density of Patients with Active Ankylosing Spondylitis with Low Bone Mineral Density
    Li, Haibo
    Li, Qiuxia
    Chen, Xi
    Ji, Chen
    Gu, Jieruo
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (08) : 1413 - 1417
12345